Chaga for Fatty Liver Disease: NAFLD Evidence

Chaga & Liver Health

1 Core Study

One published mouse study has directly tested chaga against diet-induced fatty liver disease. It found reductions in hepatic lipid accumulation through a specific bile acid signaling pathway.

Peng et al., Eur J Pharmacol, 2022

FXR/SHP/SREBP-1c

bile acid signaling axis implicated in chaga's NAFLD effect

0 RCTs

randomized human trials have tested chaga for NAFLD

Mice only

all direct NAFLD evidence comes from rodent models

Peng et al., Eur J Pharmacol, 2022

View as image ↗

Non-alcoholic fatty liver disease (NAFLD) affects roughly 25-30% of adults globally and has become the leading chronic liver condition in both the United States and Europe. The hunt for natural agents that can reduce hepatic steatosis has turned up dozens of botanical candidates, and chaga (Inonotus obliquus) is among them. The direct evidence consists of one mouse study testing chaga against diet-induced NAFLD (Peng et al., 2022), supported by a small cluster of rodent experiments on related metabolic and hepatoprotective endpoints. No randomized controlled trial has tested chaga for NAFLD in humans at any dose. This article walks through what the Peng 2022 study actually found, what the supporting rodent work adds, and why the gap between this evidence and human clinical use remains substantial. For liver protection against chemical toxicants, see chaga and liver protection: hepatoprotective research.

What NAFLD Actually Is

NAFLD is defined by hepatic lipid accumulation (>5% of liver weight as fat) in the absence of significant alcohol consumption, viral hepatitis, or other identifiable causes. It exists on a spectrum: simple steatosis (fat accumulation without inflammation), non-alcoholic steatohepatitis (NASH, fat plus inflammation and hepatocyte injury), and progressive fibrosis that can end in cirrhosis or hepatocellular carcinoma. The central metabolic disruption is impaired handling of dietary fat and carbohydrate, with de novo lipogenesis and reduced fatty acid oxidation producing net hepatic lipid accumulation.

Pharmacological treatment options are limited. Weight loss remains the only intervention with strong evidence for reversing NAFLD histologically. The 2024 FDA approval of resmetirom (a thyroid hormone receptor β agonist) provided the first NASH-specific drug. Beyond resmetirom and off-label use of GLP-1 agonists, vitamin E, and pioglitazone, the treatment landscape is dominated by lifestyle modification. This is the context in which supplement research matters: the unmet need is large, and natural products that affect hepatic lipid metabolism at mechanistic targets (SREBP-1c, PPAR-α, AMPK) are plausible candidates.

The Peng 2022 Study: What It Tested and What It Found

Peng et al. (2022) is the only published study that directly tested I. obliquus against a diet-induced NAFLD model.^[1] The study, published in European Journal of Pharmacology, evaluated chaga and its isolated bioactive compounds for effects on hepatic lipid accumulation and identified the FXR/SHP/SREBP-1c axis as the regulatory pathway involved.

This axis is worth understanding. Farnesoid X receptor (FXR) is a nuclear receptor activated by bile acids. When FXR is activated in the liver, it induces small heterodimer partner (SHP), which in turn represses sterol regulatory element-binding protein 1c (SREBP-1c), the master transcription factor driving de novo lipogenesis. Agents that activate FXR (obeticholic acid, for example, which was developed for NASH but faced regulatory hurdles) reduce hepatic lipogenesis through this cascade. The Peng 2022 finding suggests chaga compounds engage the same pathway.

Several caveats attach to this finding. The study used a mouse model, and rodent liver metabolism differs from human liver metabolism in important ways (bile acid composition, FXR target gene sets, baseline SREBP-1c activity). The study used extracted or isolated compounds rather than crude chaga powder, meaning the dose-equivalence to consumer chaga products is uncertain. And the study has not been replicated by an independent group, so the reproducibility of the FXR/SHP/SREBP-1c effect remains a single-data-point observation.

Supporting Rodent Evidence: Metabolic Pathways

Zhang et al. (2021) administered I. obliquus extract to mice and measured effects on glycolipid metabolism. The extract regulated lipid and glucose metabolism through PI3K/Akt and AMPK/ACC pathways.^[2] These pathways are central to hepatic fat accumulation: AMPK activation suppresses acetyl-CoA carboxylase (ACC), reducing malonyl-CoA and therefore fatty acid synthesis, while also promoting fatty acid oxidation. PI3K/Akt signaling governs insulin sensitivity and glucose handling.

Xu et al. (2021) reported that I. obliquus polysaccharide ameliorated serum lipid and glucose profiles in streptozotocin-induced diabetic mice.^[3] This is a diabetes model rather than a NAFLD model, but the two conditions overlap: insulin resistance drives hepatic lipid accumulation, and improvements in glucose handling often correlate with reductions in hepatic fat.

Chiang et al. (2023) demonstrated renoprotective effects of an I. obliquus ethanol-ethyl acetate extract in a combined streptozotocin and unilateral nephrectomy model of diabetic nephropathy.^[4] Again not NAFLD, but the metabolic-complication context is adjacent.

Taken together, the supporting rodent literature is consistent with metabolic effects that could translate to NAFLD benefit, but does not directly test that outcome. The Peng 2022 study remains the only direct NAFLD data point.

Hepatoprotection in Toxin Models: Relevant but Different

Several rodent studies have tested chaga in chemical and biological liver injury models. These are distinct from NAFLD (which is a chronic metabolic disease) but inform the broader hepatoprotection question.

Xu et al. (2019) showed I. obliquus polysaccharide protected mice from Toxoplasma gondii-induced liver injury, reducing hepatic inflammation and histopathological damage.^[5] The mechanism involved modulation of inflammatory cytokines rather than direct metabolic intervention.

Ishfaq et al. (2022) tested chaga aqueous extract against microcystin-LR (a cyanobacterial hepatotoxin) and reported prevention of histopathological alterations.^[6] Microcystin causes acute toxic liver injury through different pathways than NAFLD, but the protection suggests chaga has broad hepatoprotective activity.

Chen et al. (2019) showed I. obliquus polysaccharide ameliorated dextran sulfate sodium-induced colitis by modulating Th1/Th2 and Th17/Treg balance.^[7] Colitis is not liver disease, but the inflammatory cascade modulation overlaps with NASH (the inflammatory component of progressive NAFLD), where Th17-driven inflammation is a recognized driver of fibrosis progression.

The toxin-model studies establish that chaga has anti-inflammatory and cytoprotective activity in hepatocytes under acute stress. Whether this translates to chronic dietary fatty liver is an open question that only direct NAFLD models can answer, and only Peng 2022 has attempted that test.

The Human Evidence Gap

No randomized controlled trial has tested chaga for NAFLD in humans. No observational cohort has tracked chaga use against NAFLD outcomes. No case series has reported NAFLD-specific outcomes in chaga users. The comprehensive reviews by Fordjour et al. (2023) and Ern et al. (2024) both surveyed the clinical literature and both found no human trials for any liver condition.^[8][9]

The absence of human evidence for NAFLD specifically is part of a broader pattern. Chaga has been investigated for dozens of indications in preclinical models (cancer, diabetes, colitis, viral infection, kidney protection, cognitive function), and every one of these claims rests on cell or animal work. The review by Szychowski et al. (2021) framed chaga as moving "from folk medicine to clinical use," but the clinical use envisioned is prospective rather than documented.^[10]

Why the Product You Buy May Not Match the Study

Even accepting the Peng 2022 mouse findings at face value, a consumer buying chaga for NAFLD faces a product-to-study translation problem. Windsor et al. (2025) compared commercial chaga supplements using complementary analytical techniques and documented wide variation in bioactive compound content.^[11] The Peng 2022 study used specific extracts with defined compound profiles; consumer products rarely specify their triterpenoid, polysaccharide, or polyphenol content at the level of analytical detail used in research.

Kim et al. (2020) documented that triterpenoid composition in I. obliquus depends on growth conditions, harvest timing, and extraction method.^[12] Lazic et al. (2024) showed that different extraction technologies (conventional hot water, ultrasonication, microwave-assisted) produce different compound profiles.^[13] The extract used in Peng 2022 is not directly equivalent to a powder, tincture, or 8:1 extract purchased at retail.

For a breakdown of compound delivery by product type, see chaga tea vs. tincture vs. capsule: best forms for bioactives.

The Safety Cost of Chronic Chaga Use for a Chronic Condition

NAFLD management is measured in years to decades. Any supplement taken for NAFLD would be taken chronically. Chaga's three published cases of oxalate nephropathy all involved long-term consumption: Kikuchi et al. (2014) reported failure after 6 months of daily powder use, Lee et al. (2020) described end-stage renal disease after long-term ingestion, and Kwon et al. (2022) documented nephrotic syndrome in a heavy user.^[14][15][16]

The intersection of NAFLD and kidney disease is clinically important. NAFLD is associated with increased chronic kidney disease risk independent of shared metabolic risk factors. A NAFLD patient population carries higher-than-baseline CKD prevalence, and CKD reduces oxalate clearance. This means the population most motivated to take chaga for a liver reason may include individuals at elevated risk for the kidney adverse effect chaga has been documented to cause.

For dose-related safety data, see chaga dosage guide: how much should you take?. For long-term safety evidence, see can you take chaga long-term: safety considerations.

How This Evidence Compares to Other NAFLD Botanical Research

Many botanicals have larger preclinical and clinical evidence bases for NAFLD than chaga. Silymarin (from milk thistle) has been tested in multiple human trials with mixed results on hepatic enzymes and variable effects on histology. Berberine has produced meaningful human reductions in hepatic steatosis in several randomized trials. Curcumin has a moderate-sized clinical trial literature showing enzyme improvements.

Chaga is not in this category of evidence. The claim that chaga may help NAFLD is currently a mechanistic hypothesis generated by one mouse study, supported by adjacent rodent work on metabolic pathways, and untested in any human with the condition. This is a different epistemic position than "evidence-based therapy" and should not be conflated with botanicals that have completed even modest human trials.

For the underlying bioactive compound profile that drives chaga's metabolic effects, see chaga bioactive compounds: betulinic acid, melanin, and polysaccharides.

What the Evidence Supports and What It Does Not

The Bottom Line

One mouse study (Peng 2022) directly tested chaga against diet-induced NAFLD and found effects through the FXR/SHP/SREBP-1c bile acid pathway. Supporting rodent work on glucose and lipid metabolism is consistent with potential NAFLD benefit but does not directly test that outcome. No human trial has examined chaga for NAFLD. Chronic use carries documented kidney risks that are particularly relevant to the NAFLD patient population because NAFLD and chronic kidney disease co-occur.

Frequently Asked Questions

Does chaga help with fatty liver disease?

One mouse study (Peng et al., 2022) showed chaga compounds reduced hepatic lipid accumulation in a NAFLD model through the FXR/SHP/SREBP-1c bile acid signaling pathway. No randomized controlled trial has tested chaga for NAFLD in humans. The current evidence is a mechanistic hypothesis from one preclinical study, not clinical proof of benefit.

What does chaga do to the liver?

In rodent studies, chaga has demonstrated hepatoprotective activity against chemical toxicants (Ishfaq et al., 2022; microcystin), parasitic infection (Xu et al., 2019; Toxoplasma), and diet-induced fatty liver (Peng et al., 2022). The mechanisms include anti-inflammatory effects, modulation of lipid metabolism pathways (PI3K/Akt, AMPK/ACC), and bile acid receptor engagement. None of these effects has been confirmed in human liver disease.

Is chaga safe for people with liver disease?

No clinical trial has tested chaga safety in people with any liver disease. People with NAFLD have elevated rates of chronic kidney disease, and long-term chaga consumption has produced kidney failure in three published cases (Kikuchi et al., 2014; Lee et al., 2020; Kwon et al., 2022) through oxalate nephropathy. The intersection of liver disease and kidney comorbidity is where the safety concern is sharpest.

How much chaga reverses fatty liver?

No dose has been established for NAFLD in humans. The Peng et al. (2022) mouse study used extracted compounds at rodent-scale doses that do not translate directly to human supplement products. No randomized controlled trial has tested any dose of chaga for any human liver outcome.

Is chaga better than milk thistle for fatty liver?

No head-to-head trial has compared them. Milk thistle (silymarin) has been tested in multiple human trials for NAFLD with mixed results on hepatic enzymes; chaga has not been tested in any human NAFLD trial. The current evidence base for silymarin in NAFLD is substantially larger than for chaga, regardless of effect size.

Does chaga reduce liver enzymes?

In rodent toxicity models, chaga has reduced elevated serum ALT and AST caused by chemical toxicants (Ishfaq et al., 2022). Whether chaga affects liver enzymes in human NAFLD, where ALT elevation is often modest and variable, has not been tested in any published clinical trial.

Sources & References

1. 1RTHM-00789·Peng, Ankang et al. (2022). “Inonotus obliquus and its bioactive compounds alleviate non-alcoholic fatty liver disease via regulating FXR/SHP/SREBP-1c axis..” European journal of pharmacology.Study breakdown →PubMed →↩
2. 2RTHM-00736·Zhang, Zhe et al. (2021). “Effect of Inonotus obliquus (Fr.) Pilat extract on the regulation of glycolipid metabolism via PI3K/Akt and AMPK/ACC pathways in mice..” Journal of ethnopharmacology.Study breakdown →PubMed →↩
3. 3RTHM-00729·Xu, Tanye et al. (2021). “Inonotus obliquus polysaccharide ameliorates serum profiling in STZ-induced diabetic mice model..” BMC chemistry.Study breakdown →PubMed →↩
4. 4RTHM-00819·Chiang, Kuang-Hsing et al. (2023). “Renoprotective Impacts of Inonotus obliquus Ethanol-Ethyl Acetate Extract on Combined Streptozotocin and Unilateral Nephrectomy-Induced Diabetic Nephropathy in Mice..” International journal of molecular sciences.Study breakdown →PubMed →↩
5. 5RTHM-00601·Xu, Lu et al. (2019). “The polysaccharide from Inonotus obliquus protects mice from Toxoplasma gondii-induced liver injury..” International journal of biological macromolecules.Study breakdown →PubMed →↩
6. 6RTHM-00768·Ishfaq, Pir Mohammad et al. (2022). “Inonotus obliquus aqueous extract prevents histopathological alterations in liver induced by environmental toxicant Microcystin..” Current research in pharmacology and drug discovery.Study breakdown →PubMed →↩
7. 7RTHM-00549·Chen, Yi-Fang et al. (2019). “Inonotus obliquus polysaccharide ameliorates dextran sulphate sodium induced colitis involving modulation of Th1/Th2 and Th17/Treg balance..” Artificial cells.Study breakdown →PubMed →↩
8. 8RTHM-01694·Fordjour, Eric et al. (2023). “Chaga mushroom: a super-fungus with countless facets and untapped potential..” Frontiers in pharmacology.Study breakdown →PubMed →↩
9. 9RTHM-01886·Ern, Phoebe Tee Yon et al. (2024). “Chaga Therapeutic Properties: What This 2024 Review Actually Shows.” Mycology.Study breakdown →PubMed →↩
10. 10RTHM-00722·Szychowski, Konrad A et al. (2021). “Inonotus obliquus - from folk medicine to clinical use..” Journal of traditional and complementary medicine.Study breakdown →PubMed →↩
11. 11RTHM-02209·Windsor, Coleton et al. (2025). “What This 2025 Chaga Supplement Authentication Study Actually Found.” International journal of molecular sciences.Study breakdown →PubMed →↩
12. 12RTHM-01218·Kim, Jaecheol et al. (2020). “Composition of Triterpenoids in Inonotus obliquus and Their Anti-Proliferative Activity on Cancer Cell Lines..” Molecules (Basel.Study breakdown →PubMed →↩
13. 13RTHM-00888·Lazić, Vesna et al. (2024). “The Effect of Green Extraction Technologies on the Chemical Composition of Medicinal Chaga Mushroom Extracts..” Journal of fungi (Basel.Study breakdown →PubMed →↩
14. 14RTHM-00329·Kikuchi, Yuko et al. (2014). “Chaga mushroom-induced oxalate nephropathy..” Clinical nephrology.Study breakdown →PubMed →↩
15. 15RTHM-00630·Lee, Sua et al. (2020). “Development of End Stage Renal Disease after Long-Term Ingestion of Chaga Mushroom: Case Report and Review of Literature..” Journal of Korean medical science.Study breakdown →PubMed →↩
16. 16RTHM-00775·Kwon, Ohyun et al. (2022). “Chaga mushroom-induced oxalate nephropathy that clinically manifested as nephrotic syndrome: A case report..” Medicine.Study breakdown →PubMed →↩